Full-Time

Senior Director – Global Development Lead

Early Development

Posted on 9/23/2025

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$287.3k - $478.8k/yr

+ Bonus + Share-based Long Term Incentive Program

No H1B Sponsorship

Cambridge, MA, USA + 4 more

More locations: Bothell, WA, USA | San Bruno, CA, USA | La Jolla, San Diego, CA, USA | New York, NY, USA

Hybrid

Work Location Assignment: Hybrid

Category
Medical, Clinical & Veterinary (1)
Requirements
  • MD or MD-PhD with 5-10 years of industry experience in oncology, experience in multiple myeloma preferred, track record in early phase drug development.
  • Clinical oncology experience: Board certification in oncology preferred.
  • Significant industry leadership experience in clinical, translational or basic research in biomedical sciences or one of the disciplines related to drug development.
  • Understanding of related disciplines (e.g., biostatistics, regulatory, pre-clinical pharmacology, pharmaceutical sciences).
  • Demonstrated scientific productivity (publications, abstracts, etc.).
  • Proven scientific writing skills and good communication skills.
  • Proven leadership skills with ability to defend the clinical plan at governance meetings is essential.
  • Capacity to adapt to a fast-paced and changing environment.
  • Demonstrated history of effective leadership; including cross functional and matrixed teams, managing direct reports, and experience in seeking and maintaining alignment with cross-functional leaders.
  • Demonstrates a passion for helping patients with cancer and for the science of oncology.
Responsibilities
  • Lead, develop and execute strategic development for early development assets.(myeloma focused, with opportunities to work in other MOAs and oncology therapeutic areas in the early pipeline).
  • Oversee early development assets’ development broadly within a specific indication or group of indications. Typically, work on two to three clinical programs and support the development and provide consultation regarding multiple research projects.
  • Work across the organization and on multifunctional teams responsible for the development of early development assets (including Product Team).
  • Oversee the development and management of clinical protocols and amendments, investigator brochures, clinical study reports, statistical analysis plan, and regulatory documents.
  • Provide leadership to early stage clinical scientists on the clinical study team for Early Development Assets, working in a matrix team environment with other clinicians, statisticians, clinical pharmacologists, translational biologists and regulatory specialists. Meet regularly with the Pfizer Oncology group leaders/surrogates across functions to increase mutual awareness and influence of emerging program targets, priorities and status.
  • Implementation of PK-guided dose escalation, early combination strategies and emerging innovations on all Pfizer Oncology first-in-human clinical trials with input from Oncology Research Unit, Oncology Regulatory Strategy, Clinical Pharmacology and Precision Medicine, Oncology Clinical Development and Operations, Pharm Sci and Product Teams.
  • Oversee the evaluation of safety, pharmacology, and efficacy data from ongoing and completed studies for early development assets.
  • Oversee manuscripts, abstracts and presentations for scientific meetings and advisory boards.
  • Conduct literature reviews and prepare summaries to support clinical development programs.
  • Medical resource for design and interpretation of clinical and preclinical programs to support existing and new development candidates.
  • Coordinate regular (at least quarterly and as needed) interactions with preferred clinical trials network and KOL advisory board to objectively consider and implement feedback.
  • Drive innovations in early clinical development, and the application of translational oncology and precision medicine approaches.
  • Collaborates with cross-functional leaders and teams to translate early preclinical discovery research into therapeutic candidates.
  • Coordinates with business development to establish strategic external collaborations and foster new research projects and programs.
Desired Qualifications
  • Has a strong leadership presence and the ability to work effectively with other clinical and scientific leaders.
  • Has a collaborative style with internal company leadership, external development partners and investigators/medical professionals.
  • Is a team player, works well in a team environment both as a leader and a key contributor.
  • Has a global perspective and mindset, with the ability to work effectively with colleagues from myriad cultures, backgrounds, and geographies.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology biosimilars grow 52% operationally in Q1 2026 amid high-margin expansion.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma treatment positioning.
  • PF-08653944 advances to 10 Phase 3 trials in 2026 with 9.6mg dose.

What critics are saying

  • Eliquis patent expires 2028, generics erode $6B annual revenue 70% in 12 months.
  • Ibrance generics launch 2027, slash $5B sales 60-80% within 18 months.
  • Danuglipron discontinued April 2025 after liver injury in early trials.

What makes Pfizer unique

  • VEPPANU secures FDA approval as first PROTAC therapy for ESR1-mutated breast cancer.
  • VYNDAMAX patent settlements extend US exclusivity to June 2031.
  • PF-08653944 achieves 12.3% placebo-adjusted weight loss monthly in Phase 2b VESPER-3.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE